BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The resulting BCR-ABL1 fusion gene encodes for a constitutively active tyrosine kinase, which is pivotal in the pathogenesis of CML and can be inhibited by tyrosine kinase inhibitors (TKIs).